Now Available Online: Archived recording of CIBRN virtual review webinar #4 led by Dr. Mark Kirchhof

We invite you to view the archived recording of the virtual review webinar which was held on October 18, 2018, led by Dr. Mark Kirchhof featuring the recent article in the British Journal of Dermatology by Blauvelt et al: Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

NOTE: If you would like a full-text copy of the article above, please contact paul.abbass@legitimed.com

Click to view video: http://bit.ly/2ywVSj9

Now Available Online: Archived recording of CIBRN virtual review webinar #3 led by Dr. Gordon Searles

We invite you to view the archived recording of the virtual review webinar which was held on September 20th, led by Dr. Gordon Searles featuring the recent article in Advances in Therapy by Numan et al: Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies [link to full text]

Click to view video: http://bit.ly/2OGSfk2

Join Dr. Mark Kirchhof Oct 18, 8pm ET for virtual review of “Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches” (Blauvelt et al, Br J Dermatol, Jun 2018).

Please join Dr. Mark Kirchhof for WEBINAR 4 of 2018 to be held Thursday, October 18 at 8pm EST, focused on the recent article in the British Journal of Dermatology by Blauvelt et al:

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

NOTE: If you would like a full-text copy of the article above, please contact paul.abbass@legitimed.com

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com

Join Dr. Gordon Searles Sep 20, 8pm ET for virtual review of “Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies” (Numan et al, Adv Ther, Sep 2018).

Please join Dr. Gordon Searles for WEBINAR 3 of 2018 to be held Thursday, September 20 at 8pm EST, focused on the recent article in Advances in Therapy by Numan et al:

Link to full text article: Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com

Now Available Online: Archived recording of virtual review webinar #2 led by Dr. Philip Baer

We invite you to view the archived recording of the virtual review webinar which was held on June 20th, led by Dr. Philip Baer featuring the article “Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab” (Tweehuysen et al, Arthritis Rheumatol, Jan 2018) [link to full-text article]

Click to view video: http://bit.ly/2uqEXN1

Now Available Online: Archived recording of virtual review webinar #1 led by Dr. Vipul Jairath of the SECURE article (Strik et al, Lancet Gastroenterol Hepatol, Mar 2018)

We invite you to view the archived recording of the virtual review webinar which was held on May 14th and led by Dr. Vipul Jairath (CIBRN Chair) featuring the March 2018 article by Strik et al in The Lancet Gastroenterology & Hepatology: “Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial” [article abstract]

Click to view video: http://bit.ly/2Jss0ac

 

Join Dr. Philip Baer June 20, 8pm ET for webinar featuring a virtual review of “Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab” (Tweehuysen et al, Arthritis Rheumatol, Jan 2018).

Please join Dr. Philip Baer for WEBINAR 2 of 2018 to be held Wednesday, June 20 at 8pm EST, focused on the recent article in Arthritis & Rheumatology by Tweehuysen et al:

Link to full text article:  Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

For webinar access details, see calendar invitation, or email sent to you on June 5.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com